Evidence map›Paper›PMID 24369540›Full record

ReviewJournal of diabetes research2013

Making sense in antisense: therapeutic potential of noncoding RNAs in diabetes-induced vascular dysfunction.

Suzanne M Eken, Hong Jin, Ekaterina Chernogubova, Lars Maegdefessel

Abstract readReview
In one paragraph

Review in Journal of diabetes research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Suzanne M EkenAtherosclerosis Research Unit, Department of Medicine, Center for Molecular Medicine (CMM L8), Karolinska Institute, 17176 Stockholm, Sweden.
Hong JinAtherosclerosis Research Unit, Department of Medicine, Center for Molecular Medicine (CMM L8), Karolinska Institute, 17176 Stockholm, Sweden.
Ekaterina ChernogubovaAtherosclerosis Research Unit, Department of Medicine, Center for Molecular Medicine (CMM L8), Karolinska Institute, 17176 Stockholm, Sweden.
Lars MaegdefesselAtherosclerosis Research Unit, Department of Medicine, Center for Molecular Medicine (CMM L8), Karolinska Institute, 17176 Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid rise of type II diabetes mellitus and its accompanying vascular complications call for novel approaches in unravelling its pathophysiological mechanisms and designing new treatment modalities. Noncoding RNAs represent a class of previously unknown molecular modulators of this disease. The most important features of diabetes-induced vascular disease, which include metabolic deregulation, increased oxidative stress, release of inflammatory mediators like adipokines, and pathologic changes in vascular cells, all are depicted and governed by a certain set of noncoding RNAs. While these mechanisms are being unravelled, new diagnostic and therapeutic opportunities to treat diabetes-induced vascular disease emerge.

Indexed as

AnimalsDiabetic AngiopathiesHumansHyperglycemiaInsulinMicroarray AnalysisRNA, AntisenseRNA, UntranslatedInsulinRNA, AntisenseRNA, Untranslated

Identifiers

PMID24369540
PMCPMC3863503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.